Clinical trials: Renal Pelvic Urothelial Carcinoma
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
This randomized phase III trial studies gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride and cisplatin in treating patients with urinary tract cancer that has…
- Conditions
- Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT00942331
- Testing
- Bevacizumab, Cisplatin, Gemcitabine Hydrochloride
- Where
- 873 sites in United States, Puerto Rico
- Volunteers
- 506 people
- Sponsor
- National Cancer Institute (NCI)
Transitional Cell Carcinoma
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Biological therapies, such as Bacille Calmette Guerin (BCG) and sargramostim (GM-CSF), use different ways to stimulate the…
- Trial name
- NCT00070070
- Testing
- TICE®-strain BCG, NY-ESO-1 protein, sargramostim
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ludwig Institute for Cancer Research
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well vorinostat works in treating patients with locally recurrent or metastatic cancer of…
- Conditions
- Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00363883
- Testing
- vorinostat, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Distal Urethral Cancer, Proximal Urethral Cancer
Pazopanib in Treating Patients With Metastatic Urothelial Cancer
This phase II trial is studying the side effects and how well pazopanib works in treating patients with metastatic urothelial cancer.
- Conditions
- Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00471536
- Testing
- pazopanib hydrochloride
- Where
- 9 sites in United States, China and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
This phase II trial is studying how well sorafenib works in treating patients with advanced or metastatic cancer of the urinary tract.
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT00112671
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Carcinoma, Transitional Cell
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and cisplatin in patients with advanced bladder cancer.
- Conditions
- Bladder Cancer, Carcinoma, Transitional Cell, Renal Pelvis Cancer, Ureter Cancer
- Trial name
- NCT02300610
- Testing
- Enzalutamide, Cisplatin, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Renal Pelvis and Ureter Urothelial Carcinoma
Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
This phase Ib trial studies the side effects of infigratinib before surgery in treating patients with upper tract urothelial cancer.
- Trial name
- NCT04228042
- Testing
- Infigratinib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma of Urinary Tract, Urethral Carcinoma
Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
This multicenter trial will enroll participants with metastatic transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis who have had disease progression on first-line platinum-based chemotherapy regimens.
- Conditions
- Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
- Trial name
- NCT01282463
- Testing
- Docetaxel, Ramucirumab DP, Icrucumab
- Where
- 32 sites in United States, Canada
- Volunteers
- 148 people
- Sponsor
- Eli Lilly and Company
Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
This phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without berzosertib works in treating patients with urothelial cancer that has spread to other places in the body (metastatic).
- Conditions
- Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Trial name
- NCT02567409
- Testing
- Berzosertib, Cisplatin, Gemcitabine Hydrochloride
- Where
- 39 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Gemcitabine and Cisplatin are standard chemotherapy drugs used to treat advanced urothelial cancer. There is no standard chemotherapy for patients who cannot receive Cisplatin.
- Trial name
- NCT01622660
- Testing
- Gemcitabine, Pazopanib
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
This phase II trial studies the side effects of avelumab and how well it works in combination with fluorouracil and mitomycin or cisplatin and radiation therapy in treating participants with muscle-invasive bladder cancer.
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8
- Trial name
- NCT03617913
- Testing
- Avelumab, Cisplatin, Fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
This phase II trial studies how well atezolizumab when given with glycosylated recombinant human interleukin-7 (CYT107) works in treating patients with urothelial carcinoma that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma
- Trial name
- NCT03513952
- Testing
- Atezolizumab, Biopsy, Biospecimen Collection
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Bladder, Distal Urethral Cancer
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent, locally advanced, or metastatic cancer of the urothelium.
- Conditions
- Adenocarcinoma of the Bladder, Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer
- Trial name
- NCT00407485
- Testing
- ziv-aflibercept, pharmacological study
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Stage 0a Renal Pelvis and Ureter Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8
Gemcitabine for the Prevention of Intravesical Recurrence of Urothelial Cancer in Patients With Upper Urinary Tract Urothelial Cancer Undergoing Radical Nephroureterectomy, GEMINI Study
This phase II trial studies how well gemcitabine works in preventing urothelial cancer from coming back within the bladder (intravesical recurrence) in patients with upper urinary tract urothelial cancer undergoing radical…
- Conditions
- Stage 0a Renal Pelvis and Ureter Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8, Stage 0a Ureter Cancer AJCC v8, Stage 0is Renal Pelvis and Ureter Cancer AJCC v8
- Trial name
- NCT04398368
- Testing
- Gemcitabine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
This phase III trial compares survival in urothelial cancer patients who stop immune checkpoint inhibitor treatment after being treated for about a year to those patients who continue treatment with immune checkpoint inhibitors.
- Conditions
- Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma
- Trial name
- IMAGINE (NCT04637594)
- Testing
- Pembrolizumab, Nivolumab, Atezolizumab
- Where
- 377 sites in United States
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Urothelial Carcinoma
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
- Trial name
- RANGE (NCT02426125)
- Testing
- Ramucirumab, Docetaxel
- Where
- 141 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Eli Lilly and Company
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to…
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT04871529
- Testing
- Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Transitional Cell Carcinoma of Bladder, Urethra Cancer
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who…
- Conditions
- Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis
- Trial name
- NCT01326871
- Testing
- Cisplatin, Gemcitabine, ALT-801
- Where
- 16 sites in United States
- Volunteers
- 68 people
- Sponsor
- Altor BioScience
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00397488
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center